| Autor: |
Fujisaki N; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Suwazono S; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan.; Center for Clinical Neuroscience, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Suehara M; Department of Neurology, Fujimoto General Hospital/Fujimoto Medical System, Miyakonojou, Japan., Nakachi R; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Kido M; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Fujiwara Y; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Oshiro S; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Tokashiki T; Department of Neurology, National Hospital Organization Okinawa National Hospital, Ginowan, Japan., Takashima H; Department of Neurology and Geriatrics, Kagoshima University, Graduate School of Medical and Dental Sciences, Kagoshima, Japan., Nakagawa M; North Medical Center, Kyoto Prefectural University of Medicine, Kyoto, Japan. |
| Abstrakt: |
Hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) is a motor and sensory neuronopathy with autosomal dominant inheritance, adult onset, slowly progressive course, and is associated with TRK-fused gene (TFG) mutation. At advanced stages, respiratory failure and dysphagia becomes life-threatoning, and patients typically die by their 70s. Although there is currently no evidence for effective treatment, a therapy may be found by elucidation of the function of TFG. Recently its pathomechanism has been proposed to be associated with abnormalities in protein transfer from the endoplasmic reticulum. Such pathomechanisms might involve a similar process in amyotrophic lateral sclerosis; thus, its pathomechanisms and treatment strategy might make it a good model for neurodegenerative disorders. It is of great value to clarify the natural history of HMSN-P, in oder to judge the treatment effect. By evaluating 97 patients (79 out of 97 were examined and all confirmed with p.Pro 285 Leu mutation) in this study, it was confirmed that this disease follows a uniform course in the earlier stages, and there are individual differences in the onset between 20 and 30 years. Such uniformity might be due to the proposed single gene abnormality. At advanced stages, there are larger individual differences in the progression, but the reasons for these are unknown. Longer survival might be achieved with a better care for respiratory failure and dysphagia if such cares were undertaken at appropriate times. |
